Evidence map›Paper›PMID 28170001›Full record

ArticleTranslational psychiatry2017

The MCP-4/MCP-1 ratio in plasma is a candidate circadian biomarker for chronic post-traumatic stress disorder.

C Dalgard, O Eidelman, C Jozwik, C H Olsen, M Srivastava, R Biswas, Y Eudy, S W Rothwell, G P Mueller, P Yuan and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. CCL13 and human diseases.Frontiers in immunology · 2023
    Review
  11. Article
  12. Article
  13. MCP-1: Function, regulation, and involvement in disease.International immunopharmacology · 2021
    Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 2 countries.

C DalgardDepartment of Anatomy, Physiology and Genetics, Uniformed Services University School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
O EidelmanDepartment of Anatomy, Physiology and Genetics, Uniformed Services University School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
C JozwikCollaborative Health Initiative Research Program (CHIRP), Uniformed Services University School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
C H OlsenDepartment of Preventive Medicine and Biometrics, Uniformed Services University School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
M SrivastavaDepartment of Anatomy, Physiology and Genetics, Uniformed Services University School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
R BiswasDepartment of Anatomy, Physiology and Genetics, Uniformed Services University School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Y EudyDepartment of Anatomy, Physiology and Genetics, Uniformed Services University School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
S W RothwellDepartment of Anatomy, Physiology and Genetics, Uniformed Services University School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
G P MuellerDepartment of Anatomy, Physiology and Genetics, Uniformed Services University School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
P YuanMood and Anxiety Disorders Branch, National Institute for Mental Health, Bethesda, MD, USA.
W C DrevetsJanssen Research & Development, LLC, of Johnson and Johnson, Titusville, NJ, USA.
H K ManjiJanssen Research & Development, LLC, of Johnson and Johnson, Titusville, NJ, USA.
M VythlingamUnited States Department of Defense, Washington, DC, USA.
D S CharneyOffice of the Dean, Mount Sinai Medical School, New York, NY, USA.
A NeumeisterMitsubishi Tanabe Pharma Development America, Jersey City, NJ, USA.
R J UrsanoDepartment of Psychiatry, Uniformed Services University School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
D M JacobowitzDepartment of Anatomy, Physiology and Genetics, Uniformed Services University School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
H B PollardDepartment of Anatomy, Physiology and Genetics, Uniformed Services University School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
O BonneDepartment of Psychiatry, Hadassah Medical Center, Jerusalem, Israel.
Uniformed Services University of the Health Sciences · USHadassah Medical Center · ILJanssen (United States) · USJohnson & Johnson (United States) · USMitsubishi Corporation (United States) · USNational Institute of Mental Health · USUnited States Department of Defense · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-traumatic stress disorder (PTSD) is psychiatric disease, which can occur following exposure to traumatic events. PTSD may be acute or chronic, and can have a waxing and waning course of symptoms. It has been hypothesized that proinflammatory cytokines and chemokines in the cerebrospinal fluid (CSF) or plasma might be mediators of the psychophysiological mechanisms relating a history of trauma exposure to changes in behavior and mental health disorders, and medical morbidity. Here we test the cytokine/chemokine hypothesis for PTSD by examining levels of 17 classical cytokines and chemokines in CSF, sampled at 0900 hours, and in plasma sampled hourly for 24 h. The PTSD and healthy control patients are from the NIMH Chronic PTSD and healthy control cohort, initially described by Bonne et al. (2011), in which the PTSD patients have relatively low comorbidity for major depressive disorder (MDD), drug or alcohol use. We find that in plasma, but not CSF, the bivariate MCP4 (CCL13)/ MCP1(CCL2) ratio is ca. twofold elevated in PTSD patients compared with healthy controls. The MCP-4/MCP-1 ratio is invariant over circadian time, and is independent of gender, body mass index or the age at which the trauma was suffered. By contrast, MIP-1β is a candidate biomarker for PTSD only in females, whereas TARC is a candidate biomarker for PTSD only in males. It remains to be discovered whether these disease-specific differences in circadian expression for these specific immune signaling molecules are biomarkers, surrogates, or drivers for PTSD, or whether any of these analytes could contribute to therapy.

Indexed as

AdultBiomarkersChemokine CCL17Chemokine CCL2Chemokine CCL4Chronic DiseaseCircadian RhythmCytokinesFemaleHumansMaleMonocyte Chemoattractant ProteinsSex FactorsStress Disorders, Post-TraumaticBiomarkersCCL13 protein, humanCCL17 protein, humanCCL2 protein, humanChemokine CCL17Chemokine CCL2Chemokine CCL4CytokinesMonocyte Chemoattractant Proteins

Identifiers

PMID28170001
PMCPMC5438024
OpenAlexW2587625127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.